Impliant Ltd. Receives FDA Approval To Begin Pivotal Clinical Trial For Patented TOPS(TM) System

Published: Aug 23, 2006

Impliant, Inc. (www.impliant.com), a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that it has received Conditional Approval from the FDA to enroll patients in a pivotal IDE trial. The patented TOPS™ System is the world's first total posterior motion preservation system to address the leading pathologies of the posterior spinal column.

Back to news